Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: May 13, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina's stockholders have re-elected Daniel Bradbury and Roy Whitfield to serve on the firm's board of directors for three years and Gerald Möller to serve on the board for two years.

Bradbury has been a director of Illumina since 2004, while Whitfield has been a member of the board since 2007. Möller was named a director last year.


Waters has appointed William Curry, who currently serves as company VP and corporate controller, to the post of principal accounting officer. Curry has been at the firm as a corporate controller since 1999.


Proteros Biostructures has appointed David Lemus to take over the role of chairman of the board, and Rainer Metternich to be deputy chairman of the board, the protein structure and analysis company said this week. Lemus formerly was executive VP and CFO at MorphoSys, where he spent 13 years and helped the firm become a public company. Metternich, who previously was VP and basic research site head at Merck, will head Proteros' R&D/Lead Discovery committee.


Foundation Medicine has appointed Michael Pellini to be company president and CEO, where he will succeed Alexis Borisy, who will continue with the company as chairman of the board of directors. Pellini formerly was COO at Clarient, and was with the company when it was acquired by GE Healthcare in 2010. He also formerly was VP of life sciences at Safeguard Scientifics and CEO of Genomics Collaborative, which was acquired by SeraCare Life Sciences.


Biocept this week said it has named Lyle Arnold senior vice president and chief scientific officer and Michael Dunn senior vice president of corporate development. Arnold is a founder and director of Aegea Biotechnologies and was previously vice president of research at Gen-Probe. He has also held senior scientific and management positions at Genta, Synteni, and Incyte Genomics and was a co-founder of Molecular Biosystems and Oasis Biosciences.


Rosetta Genomics said this week that Moshe Many has resigned from the company's board of directors. Moshe is leaving the board "due to time constraints from other professional commitments," the company said.


Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.